Drug resistance and viral load in NUCA 3002: A comparative trial of lamivudine (3TC) (high or low dose)/zidovudine (ZDV) combination therapy vs ZDV/dideoxycytidine (ddC) combination therapy in ZDV-experienced (>=24 weeks) patients (CD4 cells 100-300/mm(3))
Publication
, Conference
Johnson, VA; Wagner, SF; Overbay, CB; Wagner, JR; Cammack, N; Penn, CR; Rubin, M; Bartlett, JA; Fallon, MA; Quinn, JB; Benoit, SL
Published in: JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY
January 1, 1995
Duke Scholars
Published In
JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY
ISSN
1077-9450
Publication Date
January 1, 1995
Volume
10
Start / End Page
55 / 55
Publisher
LIPPINCOTT-RAVEN PUBL
Related Subject Headings
- Virology
- 4206 Public health
- 4202 Epidemiology
- 3202 Clinical sciences
- 1117 Public Health and Health Services
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Johnson, V. A., Wagner, S. F., Overbay, C. B., Wagner, J. R., Cammack, N., Penn, C. R., … Benoit, S. L. (1995). Drug resistance and viral load in NUCA 3002: A comparative trial of lamivudine (3TC) (high or low dose)/zidovudine (ZDV) combination therapy vs ZDV/dideoxycytidine (ddC) combination therapy in ZDV-experienced (>=24 weeks) patients (CD4 cells 100-300/mm(3)). In JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY (Vol. 10, pp. 55–55). LIPPINCOTT-RAVEN PUBL.
Johnson, V. A., S. F. Wagner, C. B. Overbay, J. R. Wagner, N. Cammack, C. R. Penn, M. Rubin, et al. “Drug resistance and viral load in NUCA 3002: A comparative trial of lamivudine (3TC) (high or low dose)/zidovudine (ZDV) combination therapy vs ZDV/dideoxycytidine (ddC) combination therapy in ZDV-experienced (>=24 weeks) patients (CD4 cells 100-300/mm(3)).” In JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY, 10:55–55. LIPPINCOTT-RAVEN PUBL, 1995.
Johnson VA, Wagner SF, Overbay CB, Wagner JR, Cammack N, Penn CR, et al. Drug resistance and viral load in NUCA 3002: A comparative trial of lamivudine (3TC) (high or low dose)/zidovudine (ZDV) combination therapy vs ZDV/dideoxycytidine (ddC) combination therapy in ZDV-experienced (>=24 weeks) patients (CD4 cells 100-300/mm(3)). In: JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY. LIPPINCOTT-RAVEN PUBL; 1995. p. 55–55.
Johnson, V. A., et al. “Drug resistance and viral load in NUCA 3002: A comparative trial of lamivudine (3TC) (high or low dose)/zidovudine (ZDV) combination therapy vs ZDV/dideoxycytidine (ddC) combination therapy in ZDV-experienced (>=24 weeks) patients (CD4 cells 100-300/mm(3)).” JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY, vol. 10, LIPPINCOTT-RAVEN PUBL, 1995, pp. 55–55.
Johnson VA, Wagner SF, Overbay CB, Wagner JR, Cammack N, Penn CR, Rubin M, Bartlett JA, Fallon MA, Quinn JB, Benoit SL. Drug resistance and viral load in NUCA 3002: A comparative trial of lamivudine (3TC) (high or low dose)/zidovudine (ZDV) combination therapy vs ZDV/dideoxycytidine (ddC) combination therapy in ZDV-experienced (>=24 weeks) patients (CD4 cells 100-300/mm(3)). JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY. LIPPINCOTT-RAVEN PUBL; 1995. p. 55–55.
Published In
JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY
ISSN
1077-9450
Publication Date
January 1, 1995
Volume
10
Start / End Page
55 / 55
Publisher
LIPPINCOTT-RAVEN PUBL
Related Subject Headings
- Virology
- 4206 Public health
- 4202 Epidemiology
- 3202 Clinical sciences
- 1117 Public Health and Health Services
- 1103 Clinical Sciences